Profile data is unavailable for this security.
About the company
Aligos Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronavirus infections such as, SARS-Co-V2, SARS-CoV, MERS-CoV, and other related infections. Its pipeline of drug candidates includes ALG-000184 for chronic HBV infection, ALG-055009 for MASH, ALG-097558 for coronavirus infections, and a portfolio of preclinical programs. ALG-000184 is a potential Capsid Assembly Modulator (CAM-E) for chronic HBV infection with enhanced pharmacologic properties. In the area of chronic HBV infection, its advanced drug candidate, ALG-000184, helps in disrupting the HBV lifecycle with viral suppression as well as reductions in viral antigens. Its ALG-055009 is an oral, small-molecule thyroid receptor beta agonist (THR-β) for the treatment of MASH.
- Revenue in USD (TTM)2.65m
- Net income in USD-86.46m
- Incorporated2018
- Employees70.00
- LocationAligos Therapeutics IncOne Corporate Dr., 2nd Floor, 2nd FloorSOUTH SAN FRANCISCO 94080United StatesUSA
- Phone+1 (302) 658-7581
- Fax+1 (302) 655-5049
- Websitehttps://www.aligos.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INmune Bio Inc | 50.00k | -49.89m | 38.28m | 22.00 | -- | 1.51 | -- | 765.66 | -2.14 | -2.14 | 0.0021 | 0.9546 | 0.0012 | -- | 0.0258 | 2,272.73 | -115.83 | -45.54 | -153.59 | -52.16 | -- | -- | -99,774.00 | -19,298.45 | -- | -942.22 | 0.00 | -- | -90.97 | -- | -40.24 | -- | -- | -- |
| Xilio Therapeutics Inc | 31.80m | -58.49m | 39.19m | 64.00 | -- | -- | -- | 1.23 | -0.6571 | -0.6571 | 0.3348 | -0.1562 | 0.3053 | -- | -- | 496,937.50 | -56.14 | -67.88 | -102.68 | -81.71 | -- | -- | -183.90 | -5,578.28 | -- | -2.84 | -- | -- | -- | -- | 23.77 | -- | -45.00 | -- |
| Cypherpunk Technologies Inc | 0.00 | -50.81m | 40.22m | 52.00 | -- | 10.92 | -- | -- | -1.23 | -1.23 | 0.00 | 0.065 | 0.00 | -- | -- | 0.00 | -132.94 | -79.03 | -196.76 | -93.29 | -- | -- | -- | -9,055.53 | -- | -- | 0.00 | -- | -- | -- | 16.74 | -- | -- | -- |
| Lisata Therapeutics Inc | 1.07m | -18.24m | 40.31m | 26.00 | -- | 2.30 | -- | 37.67 | -2.13 | -2.13 | 0.1246 | 1.98 | 0.0357 | -- | -- | 41,153.85 | -60.85 | -44.77 | -71.25 | -49.07 | -- | -- | -1,704.86 | -13,065.70 | -- | -- | 0.00 | -- | -- | -- | 4.10 | -- | -- | -- |
| CEL-SCI Corp | 0.00 | -25.41m | 41.20m | 43.00 | -- | 2.46 | -- | -- | -7.81 | -7.81 | 0.00 | 1.99 | 0.00 | -- | -- | -- | -92.16 | -72.20 | -111.94 | -80.91 | -- | -- | -- | -- | 2.20 | -38.20 | 0.3328 | -- | -- | -- | 7.86 | -- | -57.33 | -- |
| Aligos Therapeutics Inc | 2.65m | -86.46m | 42.52m | 70.00 | -- | 0.5919 | -- | 16.07 | -12.70 | -12.70 | 0.2964 | 11.67 | 0.0267 | -- | -- | 37,800.00 | -87.25 | -60.83 | -111.39 | -72.31 | -- | -- | -3,267.65 | -1,462.14 | -- | -- | 0.002 | -- | -74.60 | -- | -49.65 | -- | -45.83 | -- |
| OS Therapies Inc | 0.00 | -20.26m | 42.96m | 4.00 | -- | 11.16 | -- | -- | -0.9794 | -0.9794 | 0.00 | 0.1415 | 0.00 | -- | -- | 0.00 | -334.55 | -- | -870.52 | -- | -- | -- | -- | -- | -- | -2,674.49 | 0.00 | -- | -- | -- | -37.51 | -- | -- | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 43.08m | 4.00 | -- | -- | -- | 57,435.98 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| ABVC Biopharma Inc | 797.92k | -4.12m | 43.09m | 16.00 | -- | 3.35 | -- | 54.00 | -0.2223 | -0.2223 | 0.0464 | 0.4985 | 0.0448 | -- | 0.408 | 49,870.00 | -24.89 | -105.17 | -42.73 | -217.00 | 0.2469 | 75.19 | -555.90 | -2,124.21 | 0.6241 | -13.71 | 0.0662 | -- | 234.31 | -6.20 | 37.05 | -- | -- | -- |
| CervoMed Inc | 6.16m | -25.58m | 43.67m | 15.00 | -- | 1.68 | -- | 7.09 | -2.87 | -2.87 | 0.6919 | 2.81 | 0.155 | -- | 7.58 | 410,652.00 | -64.37 | -54.89 | -71.42 | -60.99 | -- | -- | -415.36 | -428.45 | -- | -- | 0.00 | -- | 36.29 | -- | -650.08 | -- | -- | -- |
| Clene Inc | 214.00k | -30.50m | 45.90m | 75.00 | -- | -- | -- | 214.46 | -3.33 | -3.33 | 0.0231 | -1.21 | 0.0079 | 0.4021 | 0.475 | 2,853.33 | -113.20 | -55.54 | -280.47 | -72.66 | 82.24 | 76.19 | -14,250.47 | -6,165.10 | 1.52 | -8.71 | 3.64 | -- | -47.71 | -- | 20.41 | -- | -- | -- |
| Kezar Life Sciences Inc | 0.00 | -61.71m | 46.14m | 55.00 | -- | 0.556 | -- | -- | -8.44 | -8.44 | 0.00 | 11.33 | 0.00 | -- | -- | 0.00 | -47.14 | -34.75 | -54.13 | -36.82 | -- | -- | -- | -5,003.10 | -- | -- | 0.0742 | -- | -100.00 | -- | 17.80 | -- | -45.57 | -- |
| Cingulate Inc | 0.00 | -22.06m | 46.21m | 13.00 | -- | 10.32 | -- | -- | -5.35 | -5.35 | 0.00 | 0.5811 | 0.00 | -- | -- | 0.00 | -183.12 | -157.80 | -264.65 | -303.36 | -- | -- | -- | -- | -- | -19.54 | 0.4783 | -- | -- | -- | 33.95 | -- | -26.92 | -- |
| Impact Biomedical Inc | 25.00k | -44.19m | 46.62m | 2.00 | -- | -- | -- | 1,864.77 | -3.76 | -3.76 | 0.0021 | -0.9691 | 0.0008 | -- | 3.33 | 12,500.00 | -136.32 | -18.99 | -260.12 | -26.29 | 52.00 | -- | -176,952.00 | -78,189.58 | 0.0182 | -0.2682 | 1.63 | -- | -- | -- | -469.83 | -- | -- | -- |
| UMeWorld Inc | 7.93k | -1.32m | 47.06m | 1.00 | -- | -- | -- | 5,934.66 | -0.0148 | -0.0148 | 0.00009 | -0.0477 | 0.1253 | -- | 1.71 | 7,930.00 | -2,066.65 | -273.32 | -- | -- | -285.62 | -768.98 | -16,497.98 | -13,102.00 | -- | -2.36 | -- | -- | 136.17 | -- | -15.02 | -- | -- | -- |
Data as of Feb 13 2026. Currency figures normalised to Aligos Therapeutics Inc's reporting currency: US Dollar USD
48.78%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Woodline Partners LPas of 30 Sep 2025 | 468.20k | 8.75% |
| Deep Track Capital LPas of 31 Dec 2025 | 444.11k | 8.30% |
| Alyeska Investment Group LPas of 31 Dec 2025 | 412.00k | 7.70% |
| Sio Capital Management LLCas of 31 Dec 2025 | 335.94k | 6.28% |
| Marshall Wace LLPas of 31 Dec 2025 | 268.66k | 5.02% |
| Readystate Asset Management LPas of 30 Sep 2025 | 203.11k | 3.79% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 171.02k | 3.20% |
| Adage Capital Management LPas of 30 Sep 2025 | 140.00k | 2.62% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 85.44k | 1.60% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 83.06k | 1.55% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
